Vaccines in civilian defense against bioterrorism

Emerging Infectious Diseases

Volumn 5, Issue 4, 1999, Pages 531-533

  Russell, Philip K ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PLAGUE VACCINE; VACCINE; VACCINIA VACCINE;

ANTHRAX; BACILLUS ANTHRACIS; BIOLOGICAL WARFARE; FOOD AND DRUG ADMINISTRATION; HUMAN; NONHUMAN; PLAGUE; SHORT SURVEY; SMALLPOX; VACCINATION;

EID: 0032843841     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0504.990413     Document Type: Short Survey

References (3)

1. Committee on R&D Needs for Improving Civilian Medical Response to Chemical and Biological Terrorism Incidents. Institute of Medicine, National Academy of Sciences. Chemical and Biological Terrorism. Research and Development to Improve Civilian Medical Response. Washington: National Academy Press; 1999.
2. Zajtchtchuk R, Bellamy RF, editors. Textbook of military medicine: medical aspects of chemical and biological warfare. Office of the Surgeon General, Department of the Army. Washington, D.C.; 1997.
3. Pomeratnsev AP, Startsin NA, Mockov YV, Marnin LI. Expression of cereolysin AB genes in Bacillus Anthracis vaccine strain ensures protection against experimental hemolytic anthrax infection. Vaccine 1997;15:1846-50.